MELAS syndrome (mitochondrial encephalopathy, lactic acidosis and stroke-like episodes) is a rare inherited disorder characterized by multiple disorders of the nervous system and other organs caused by mitochondrial dysfunction. The main clinical manifestations include neurological disorders such as migraines, stroke episodes, and metabolic disturbances including hyperlactacidemia. Developmental delay, progressive muscle weakness, and organ damage such as the heart and kidneys are also common. MELAS syndrome usually has a progressive course and remains a disease with high morbidity and mortality at a young age.
History of the disease and interesting historical facts
MELAS syndrome was first described in 1980 by Dr. Osao in Japan, after which its clinical features and hereditary nature became known. Interestingly, the manifestations of the syndrome could differ at different time periods, which sometimes misled doctors. In 1998, a group of researchers discovered that mutations in the MT-TL1 gene, which encodes mitochondrial platelet RNA, are responsible for most cases of MELAS. Since then, many other genetic variations have been identified, including changes in the MT-ND1 and MT-ND5 genes, expanding our understanding of the pathogenesis of the syndrome.
Epidemiology
The epidemiology of MELAS syndrome demonstrates its rarity. Data on the occurrence of the disease varies depending on the region, but it is generally believed that the lack of complete statistics makes it difficult to estimate its true prevalence. According to some studies, the incidence is approximately 1 case per 20,000-40,000 newborns. The highest incidence is recorded in Japan and other East Asian countries, with a lower prevalence observed in Western Europe and the United States.
Genetic predisposition to this disease
MELAS syndrome is a hereditary disorder associated with mutations in mitochondrial DNA. The main gene associated with the syndrome is MT-TL1, which is responsible for the synthesis of tRNAs required for mitochondrial protein synthesis. Mutations in this gene lead to a deficiency in bioenergetics, which causes a disruption of metabolic processes in cells. Mutations have also been identified in other mitochondrial genes, such as MT-ND1 and MT-ND5, which are also involved in the mitochondrial respiratory chain. Genetic predisposition to MELAS syndrome determines its inheritance through the maternal line, since mitochondria are transmitted exclusively through the maternal line.
Risk factors for the development of this disease
There are several risk factors that may contribute to the development of MELAS syndrome. These include:
- Heredity: presence of relatives with mitochondrial diseases.
- Gender: Although the disease affects everyone, some studies suggest that men may be more susceptible to more severe forms.
- A condition called metabolic syndrome, which is associated with elevated lactate levels.
- Environmental factors: Long-term exposure to toxic substances such as lead or mercury may worsen the condition in patients with pre-existing mitochondrial disorders.
Diagnosis of this disease
Diagnosis of MELAS syndrome involves a multi-step approach, which includes:
- Main symptoms: clinical analysis based on symptoms such as migraine episodes, intoxication, mental disorders, progressive myopathy.
- Laboratory tests: determination of plasma lactate and pyruvate levels; analysis of mitochondrial DNA mutations by sequencing.
- Radiological examinations: computed tomography or magnetic resonance imaging of the brain, which can reveal ischemic changes.
- Other types of diagnostics: muscle or skin biopsy to analyze mitochondria.
- Differential diagnosis: ruling out other causes of metabolic disorders, such as metabolic diseases and congestive heart failure.
Treatment
Treatment of MELAS syndrome is complex and multi-stage. It includes:
- General treatment: supportive therapy aimed at relieving symptoms and improving quality of life.
- Pharmacological treatment: Taking vitamins such as coenzyme Q10 and L-carnitine may help improve energy processes in the mitochondria.
- Surgical treatment: In some cases, surgery may be required to correct complications associated with the cardiovascular system.
- Other types of treatment: the use of physical therapy to rehabilitate muscle tone and function.
List of medications used to treat this disease
The main medications used to treat MELAS syndrome include:
- Coenzyme Q10.
- L-carnitine.
- Riboflavin (vitamin B2).
- Folic acid.
- Sodium citrate (to control lactate levels).
- Neuroprotectors (nootropics).
Disease monitoring
Monitoring of MELAS syndrome includes regular observation of the patient's condition. The main control stages are:
- Regular examinations to assess neurological status.
- Blood lactate and pyruvate tests.
- Monitoring of cardiological and metabolic parameters.
The prognosis of the disease can vary, with early-onset patients having more severe symptoms and a worse outcome. Complications can include severe metabolic disorders, cardiovascular disease, and disability.
Age-related features of the disease
MELAS syndrome can manifest itself at different ages, but typical moments are:
- Newborns: Symptoms such as hypotonia and failure to thrive may occur.
- Children: development of stroke and migraine episodes, as well as progressive weakness.
- Adults: more severe neurological disorders and possible cardiovascular damage.
Questions and Answers
- What is MELAS syndrome? It is a rare mitochondrial disease characterized by neurological disorders and metabolic abnormalities associated with mitochondrial dysfunction.
- What are the main symptoms of MELAS syndrome? Major symptoms include migraine episodes, strokes, cognitive decline, muscle weakness and increased lactate levels.
- How is MELAS syndrome diagnosed? Diagnosis includes clinical examination, laboratory tests for lactate levels, muscle biopsy and radiological studies.
- Is it possible to completely cure MELAS syndrome? There is currently no complete cure, but there are supportive treatments that can improve patients' quality of life.
- What is the prognosis for patients with MELAS syndrome? The prognosis depends on the age of onset and the severity of symptoms; early onset usually leads to more severe consequences.
